JNJ-56136379 + tenofovir disoproxil fumarate

**JNJ-56136379 + tenofovir disoproxil fumarate** is a combination investigational therapy for chronic hepatitis B virus (HBV) infection. JNJ-56136379, also known as bersacapavir, is a capsid assembly modulator that targets the HBV core protein, disrupting both early and late stages of viral replication. It acts primarily by accelerating capsid assembly kinetics, preventing encapsidation of polymerase-bound pregenomic RNA and leading to the formation of empty capsids, and secondarily by inhibiting the de novo formation of covalently closed circular DNA (cccDNA)[3][4]. Tenofovir disoproxil fumarate is a nucleotide analogue reverse transcriptase inhibitor approved for treatment of HBV, working by inhibiting the viral polymerase and blocking viral DNA synthesis. The combination is under clinical investigation due to the complementary mechanisms, aiming for higher HBV functional cure rates[2][5].

Other names

bersacapavir + tenofovir disoproxil fumarate